Therapeutic advances in idiopathic pulmonary fibrosis

• Published in: Clinical medicine (London, England) Vol. 16; no. 1; pp. 42 - 51
• Main Authors: Fraser, Emily, Hoyles, Rachel K
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2016; Royal College of Physicians
• Subjects: anti-fibrotic agents; Anti-Inflammatory Agents - therapeutic use; Drug Therapies In; Humans; idiopathic pulmonary fibrosis; Idiopathic Pulmonary Fibrosis - diagnosis; Idiopathic Pulmonary Fibrosis - physiopathology; Idiopathic Pulmonary Fibrosis - therapy; Indoles - therapeutic use; IPF; nintedanib; pirfenidone; Pyridones - therapeutic use; nintedanib; idiopathic pulmonary fibrosis; anti-fibrotic agents; pirfenidone; IPF

Idiopathic pulmonary fibrosis (IPF) is characterised by progressive accumulation of scar tissue in the lung and is associated with a median life expectancy of 2–4 years. Until recently, treatment options were limited, focusing on ineffective anti-inflammatory therapy, palliation, transplant or trial...